Please assess the completion status of the following clinical trial:

Trial Title: Obeticholic Acid in Pediatric Subjects With Biliary Atresia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female pediatric subjects ≥2 to \<18 years old~2. Diagnosis of biliary atresia~3. Demonstrated successful HPE (also known as Kasai portoenterostomy) as defined by total bilirubin \<2 mg/dL (34.2 μmol/L) at least 3 months post-HPE procedure.~4. Able to swallow tablets (ie, tablet or mini-tablet formulation)~Key Exclusion Criteria:~1. Prior liver transplant or active status on transplant list~2. Conjugated (direct) bilirubin ≥ULN of site specific reference range~3. If conjugated bilirubin is not available: total bilirubin ≥2 mg/dL (34.2 μmol/L)~4. Platelets \<150,000/μL~5. INR ≥1.5~6. Current or history of complications of decompensated chronic liver disease including:~   1. high-risk gastroesophageal varices and/or variceal bleeding~  2. clinically evident ascites related to portal hypertension~  3. hepatic encephalopathy~  4. prior placement of portosystemic shunt~  5. hepatopulmonary syndrome or portopulmonary hypertension~  6. hepatorenal syndrome~7. Current intractable pruritus or requires systemic treatment for pruritus within 3 months of Screening (e.g., with bile acid sequestrants or rifampicin)~8. Height and weight Z-score \<-2 per site specific ranges~9. Acholic (pale) stools~10. AST \>4x ULN~11. ALT \>4x ULN~12. GGT \>500 U/L~13. Anticoagulation therapy~14. Albumin \<3.5 g/dL~15. Ongoing current cholangitis~16. Choledochal cystic disease~17. Renal disease defined as serum creatinine \>ULN for subject's age, prior to enrollment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SD (1.5mg adult-equivalent dose of OCA) + MD Low dose (1.5mg adult-equivalent dose of OCA) (Type: EXPERIMENTAL): At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Enrollment in the Multiple Dose (MD) Phase will occur in a sequential fashion. At Day 28, the first 8 (±1) eligible subjects will be assigned to the Low Dose Cohort and will receive a 1.5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 2 OCA tablet dose strength (0.1mg and 1.5mg) are available in the study and dose will be determined using weight based dosing chart.
- SD (1.5mg adult-equivalent dose of OCA) + MD Medium dose (5mg adult-equivalent dose of OCA) (Type: EXPERIMENTAL): At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Low Dose Cohort, 8 (±1) eligible subjects will be assigned to the Medium Dose Cohort and will receive a 5 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart.
- SD (1.5mg adult-equivalent dose of OCA) + MD High dose (10mg adult-equivalent dose of OCA) (Type: EXPERIMENTAL): At Single Dose (SD) phase, eligible subjects will receive a 1.5 mg adult-equivalent, body weight-based single dose of OCA on Day 1. Upon safety and tolerability assessment in the Medium Dose Cohort, 8 (±1) eligible subjects will be assigned to the High Dose Cohort and will receive a 10 mg adult-equivalent dose of OCA daily for 4 weeks.~The adult-equivalent dose is based on a 70-kg adult. 3 OCA tablet dose strength (0.1mg, 1.5mg and 5mg tablets) are available in the study and dose will be determined using weight based dosing chart.

Based on this trial design, predict the completion outcome and termination type (if applicable).